PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26945356-3	2016	The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry.	Sofosbuvir	68-78	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	111-115	
26945356-3	2016	The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry.	Sofosbuvir	80-83	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	111-115	
24333184-3	2014	The aim is to report the HRQL of patients who participated in clinical trials of sofosbuvir (SOF) for CH-C.	Sofosbuvir	81-91	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	102-106	
24333184-4	2014	METHODS: CH-C patients were treated with sofosbuvir (SOF), pegylated interferon (PegIFN), ribavirin (RBV), or placebo in different combinations and duration (POSITRON, FISSION, FUSION, and NEUTRINO phase III trials).	Sofosbuvir	41-51	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	9-13